Telix Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Jan '24 Jan 1, 2024	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	803.79	516.55	332.98	108.81	5.52
Revenue Growth (YoY)	55.61%	55.13%	206.01%	1870.12%	37.33%
Cost of Revenue	421.95	197.06	129.7	44.29	1.85
Gross Profit	381.85	319.49	203.28	64.52	3.67
Selling, General & Admin	192.56	135.52	83.13	59.2	34.16
Research & Development	171.25	127.93	85.32	55.06	24.82
Other Operating Expenses	-1.25	0.16	-0.14	0.63	-
Operating Expenses	362.56	263.61	168.3	114.89	62.75
Operating Income	19.29	55.88	34.98	-50.37	-59.08
Interest Expense	-13.76	-4.79	-0.52	-0.22	-0.12
Interest & Investment Income	5.83	7.18	0.67	0	-
Currency Exchange Gain (Loss)	-0.56	11.9	-0.73	-0.76	1.23
Other Non Operating Income (Expenses)	-27.11	-19.65	-8.57	-4.33	10.25
EBT Excluding Unusual Items	-16.32	50.52	25.83	-55.68	-47.71
Merger & Restructuring Charges	-	-5.75	-	-	-
Asset Writedown	-0.57	0.48	-0.55	-	-
Other Unusual Items	11.62	-7.33	-22.69	-11.36	-10.8
Pretax Income	-5.27	37.92	2.59	-67.03	-58.51
Income Tax Expense	1.86	4.23	-1.61	3.71	0.03
Net Income	-7.13	33.69	4.21	-70.74	-58.54
Net Income to Common	-7.13	33.69	4.21	-70.74	-58.54
Net Income Growth	-	700.50%	-	-	-
Shares Outstanding (Basic)	338	331	319	311	282
Shares Outstanding (Diluted)	338	345	324	311	282
Shares Change (YoY)	-2.12%	6.64%	4.21%	10.08%	9.69%
EPS (Basic)	-0.02	0.10	0.01	-0.23	-0.21
EPS (Diluted)	-0.02	0.10	0.01	-0.23	-0.21
EPS Growth	-	650.77%	-	-	-
Free Cash Flow	-42.99	18.37	7.97	-48.26	-44.11
Free Cash Flow Per Share	-0.13	0.05	0.03	-0.15	-0.16
Gross Margin	47.50%	61.85%	61.05%	59.29%	66.46%
Operating Margin	2.40%	10.82%	10.51%	-46.29%	-1069.60%
Profit Margin	-0.89%	6.52%	1.26%	-65.01%	-1059.90%
Free Cash Flow Margin	-5.35%	3.56%	2.39%	-44.35%	-798.67%
EBITDA	32.46	59.64	38.17	-47.3	-55.79
EBITDA Margin	4.04%	11.54%	11.46%	-43.47%	-
D&A For EBITDA	13.17	3.75	3.19	3.07	3.29
EBIT	19.29	55.88	34.98	-50.37	-59.08
EBIT Margin	2.40%	10.82%	10.51%	-46.29%	-
Effective Tax Rate	-	11.16%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.